CD4 and cancer: Overall, our immunological outcomes are in phase with most of those presented in the work by Briere et al. on MRTX849 used alone in preclinical models of KRASG12C mutated cancers, including an increase in the proportion of CD4+ T cells, CD4+ helper T cells and CD8+ T cells [26].